These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23503489)

  • 1. Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, Brazil.
    Ferreira AC; Silva Júnior JL; Conde MB; Rabahi MF
    J Bras Pneumol; 2013; 39(1):76-83. PubMed ID: 23503489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of tuberculosis patients in the city of Porto Alegre, Brazil: outcomes.
    Picon PD; Rizzon CF; Bassanesi SL; Silva LC; Della Giustina Mde L
    J Bras Pneumol; 2011; 37(4):504-11. PubMed ID: 21881741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Strategy for Rifampin-Susceptible Tuberculosis.
    Paton NI; Cousins C; Suresh C; Burhan E; Chew KL; Dalay VB; Lu Q; Kusmiati T; Balanag VM; Lee SL; Ruslami R; Pokharkar Y; Djaharuddin I; Sugiri JJR; Veto RS; Sekaggya-Wiltshire C; Avihingsanon A; Sarin R; Papineni P; Nunn AJ; Crook AM;
    N Engl J Med; 2023 Mar; 388(10):873-887. PubMed ID: 36808186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.
    Macnab MF; Bohmer PD; Seager JR
    S Afr Med J; 1994 Jun; 84(6):325-8. PubMed ID: 7740377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health].
    Maciel EL; Guidoni LM; Favero JL; Hadad DJ; Molino LP; Jonhson JL; Dietze R
    J Bras Pneumol; 2010; 36(2):232-8. PubMed ID: 20485945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.
    Al-Shaer MH; Mansour H; Elewa H; Salameh P; Iqbal F
    BMC Infect Dis; 2017 Feb; 17(1):118. PubMed ID: 28152986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection.
    Jones BE; Otaya M; Antoniskis D; Sian S; Wang F; Mercado A; Davidson PT; Barnes PF
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1499-502. PubMed ID: 7952606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
    Guo N; Marra F; Fitzgerald JM; Elwood RK; Marra CA
    Eur Respir J; 2010 Jul; 36(1):206-8. PubMed ID: 20595167
    [No Abstract]   [Full Text] [Related]  

  • 12. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
    García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions observed during DOTS.
    Dhingra VK; Rajpal S; Aggarwal N; Aggarwaln JK; Shadab K; Jain SK
    J Commun Dis; 2004 Dec; 36(4):251-9. PubMed ID: 16506547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antituberculosis agents.
    Goldberger MJ
    Med Clin North Am; 1988 May; 72(3):661-8. PubMed ID: 3280912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antituberculous agents.
    Van Scoy RE; Wilkowske CJ
    Mayo Clin Proc; 1987 Dec; 62(12):1129-36. PubMed ID: 3682957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of tuberculosis].
    Ben Amar J; Dhahri B; Aouina H; Azzabi S; Baccar MA; El Gharbi L; Bouacha H
    Rev Pneumol Clin; 2015; 71(2-3):122-9. PubMed ID: 25434510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.